

BC Cancer Protocol Summary for the Treatment of Relapsed or Refractory Hodgkin Lymphoma Using 4-Weekly Nivolumab

Protocol Code

LYNIV4

Tumour Group

Lymphoma

Contact Physician

Dr. Kerry Savage

ELIGIBILITY:

- Classical Hodgkin lymphoma, relapsed or progressed after autologous stem cell transplantation (ASCT) and brentuximab vedotin
- Patients with relapsed or refractory cHL not eligible for ASCT and relapsed or progressed after brentuximab vedotin
- Patients with relapsed or refractory cHL with contraindication to brentuximab vedotin (e.g., peripheral neuropathy)
- Good performance status
- Adequate hepatic and renal function
- Access to a treatment centre with expertise to manage immune-mediated adverse reactions of nivolumab
- CAP approval is not required to switch between LYNIV and LYNIV4
- Patients are funded to receive either nivolumab (LYNIV or LYNIV4) or pembrolizumab (LYPEM or LYPEM6), but not both

EXCLUSIONS:

- Active autoimmune disease
- Use with caution in patients with long term immunosuppressive therapy or systemic corticosteroids (Requiring more than 10 mg prednisone/day or equivalent)

TESTS:

- Baseline: CBC & Diff, creatinine, alkaline phosphatase, ALT, total bilirubin, LDH, sodium, potassium, TSH, morning serum cortisol, chest x-ray
- Baseline (required, but results do not have to be available to proceed with first treatment; results must be checked before proceeding with cycle 2): HBsAg, HBsAb, HBcoreAb
- Before each treatment: CBC & Diff, creatinine, alkaline phosphatase, ALT, total bilirubin, LDH, sodium, potassium, TSH
- If clinically indicated: chest x-ray, morning serum cortisol, lipase, serum or urine HCG (required for woman of child bearing potential if pregnancy suspected), Free T3 and Free T4, serum ACTH levels, testosterone, estradiol, FSH, LH, ECG, C-reactive protein (CRP), creatinine kinase (CK), troponin
- If clinically indicated: HBV viral load (see protocol [SCHBV](#))
- Weekly telephone nursing assessment for signs and symptoms of side effects while on treatment (Optional).

PREMEDICATIONS:

- Antiemetics are not usually required.
- Antiemetic protocol for low emetogenicity (see SCNAUSEA).
- If prior infusion reactions to nivolumab: diphenhydrAMINE 50 mg PO, acetaminophen 325 to 975 mg PO, and hydrocortisone 25 mg IV 30 minutes prior to treatment

SUPPORTIVE MEDICATIONS:

Moderate risk of hepatitis B reactivation. If HBsAg or HBcoreAb positive, follow hepatitis B prophylaxis as per [SCHBV](#).

TREATMENT:

Drug	Dose	BC Cancer Administration Guideline
nivolumab	6 mg/kg (maximum 480 mg)	IV in 50 to 100 mL NS over 30 minutes using a 0.2 micron in-line filter

- Repeat **every 4 weeks** until disease progression or unacceptable toxicity
- If pseudo progression on imaging is suspected, may continue treatment for another 8 weeks. Discontinue treatment if confirmatory progression on subsequent scan (8-12 weeks)

DOSE MODIFICATIONS:

No specific dose modifications. Toxicity managed by treatment delay and other measures (see [SCIMMUNE](#) protocol for management of immune-mediated adverse reactions to checkpoint inhibitors immunotherapy).

PRECAUTIONS:

- **Serious immune-mediated reactions:** these can be severe to fatal and usually occur during the treatment course. They may include enterocolitis, intestinal perforation or hemorrhage, hepatitis, dermatitis, neuropathy, endocrinopathy, as well as toxicities in other organ systems. Early diagnosis and appropriate management are essential to minimize life-threatening complications (see [SCIMMUNE](#) protocol for management of immune-mediated adverse reactions to checkpoint inhibitors immunotherapy).
- **Infusion-related reactions:** isolated cases of severe reaction have been reported. In case of a severe reaction, nivolumab infusion should be discontinued and appropriate medical therapy administered. Patients with mild or moderate infusion reaction may receive nivolumab with close monitoring. Premedications with acetaminophen and anti-histamine may be considered if there is a history of reaction.
- **Hepatitis B Reactivation:** See [SCHBV](#) protocol for more details.

Call Dr. Kerry Savage or tumour group delegate at (604) 877-6000 or 1-800-663-3333 with any problems or questions regarding this treatment program.

References:

1. Younes A, Santoro A, Shipp M, et al. Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial. *Lancet Oncol* 2016;17(9):1283-94.
2. Weber JS, et al. Management of adverse events following treatment with anti-programmed death-1 agents. *Oncologist* 2016;21:1-11.